Reports for APOTEX INC
Formerly known as AA PHARMA INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
26 (7%)
Discontinued:
343 (93%)
Reversed:
0 (0%)
369
145 (4%)
73 (30%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-HYDROXYQUINE | 200MG | TABLET | Resolved | 2020-03-20 | 2020-04-24 | 109087 |
| APO-HYDROXYQUINE | 200MG | TABLET | Resolved | 2017-09-04 | 2017-11-20 | 20875 |
| APO-HYDROXYQUINE | 200MG | TABLET | Resolved | 2024-07-18 | 2024-09-20 | 233330 |
| APO-HYDROXYQUINE | 200MG | TABLET | Resolved | 2025-03-13 | 2025-03-28 | 252548 |
| APO-HYDROXYUREA | 500MG | CAPSULE CAPSULE | Resolved | 2023-02-02 | 2023-02-09 | 183489 |
| APO-HYDROXYUREA | 500MG | CAPSULE | Resolved | 2019-08-08 | 2020-06-24 | 91143 |
| APO-HYDROXYUREA | 500MG | CAPSULE CAPSULE | Resolved | 2022-12-09 | 2023-01-31 | 177609 |
| APO-HYDROXYUREA | 500MG | CAPSULE | Resolved | 2017-08-14 | 2017-12-07 | 19129 |
| APO-HYDROXYUREA | 500MG | CAPSULE CAPSULE | Resolved | 2023-08-18 | 2023-09-12 | 202406 |
| APO-HYDROXYUREA | 500MG | CAPSULE CAPSULE | Resolved | 2020-08-14 | 2020-11-18 | 122276 |
| APO-HYDROXYUREA | 500MG | CAPSULE CAPSULE | Resolved | 2025-01-30 | 2025-04-11 | 249096 |
| APO-IBUPROFEN | 200MG | TABLET | Resolved | 2024-03-01 | 2024-03-29 | 221087 |
| APO-IBUPROFEN | 200MG | TABLET | Resolved | 2022-02-11 | 2022-05-14 | 154762 |
| APO-IBUPROFEN | 400MG | TABLET | Resolved | 2023-01-06 | 2023-02-09 | 180109 |
| APO-IBUPROFEN | 400MG | TABLET | Resolved | 2024-03-15 | 2024-04-05 | 222470 |
| APO-IBUPROFEN | 400MG | TABLET | Resolved | 2021-03-19 | 2021-06-07 | 136019 |
| APO-IBUPROFEN | 400MG | TABLET | Resolved | 2021-04-09 | 2021-05-01 | 137250 |
| APO-IBUPROFEN TAB 200MG | 200MG | TABLET | Resolved | 2019-02-24 | 2020-04-01 | 76717 |
| APO-IBUPROFEN TAB 600MG | 600MG | TABLET | Resolved | 2024-01-12 | 2024-03-29 | 215967 |
| APO-IBUPROFEN TAB 600MG | 600MG | TABLET | Resolved | 2023-04-14 | 2023-04-21 | 189638 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |